Back to Search
Start Over
Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID.
- Source :
-
Journal of the American Heart Association [J Am Heart Assoc] 2021 Jun 15; Vol. 10 (12), pp. e018684. Date of Electronic Publication: 2021 May 31. - Publication Year :
- 2021
-
Abstract
- Background Peripheral artery disease (PAD) and heart failure (HF) are each independently associated with poor outcomes. Risk factors associated with new-onset HF in patients with primary PAD are unknown. Furthermore, how the presence of HF is associated with outcomes in patients with PAD is unknown. Methods and Results This analysis examined risk relationships of HF on outcomes in patients with symptomatic PAD randomized to ticagrelor or clopidogrel as part of the EUCLID (Examining Use of Ticagrelor in Peripheral Arterial Disease) trial. Patients were stratified based on presence of HF at enrollment. Cox models were used to determine the association of HF with outcomes. A separate Cox model was used to identify risk factors associated with development of HF during follow-up. Patients with PAD and HF had over twice the rate of concomitant coronary artery disease as those without HF. Patients with PAD and HF had significantly increased risk of major adverse cardiovascular events (hazard ratio [HR], 1.31; 95% CI, 1.13-1.51) and all-cause mortality (HR, 1.39; 95% CI, 1.19-1.63). In patients with PAD, the presence of HF was associated with significantly less bleeding (HR, 0.65; 95% CI, 0.45-0.96). Characteristics associated with HF development included age ≥66 (HR, 1.29; 95% CI, 1.18-1.40 per 5 years), diabetes mellitus (HR, 1.85; 95% CI, 1.41-2.43), and weight (bidirectionally associated, ≥76 kg, HR, 0.77; 95% CI, 0.64-0.93; <76 kg, HR, 1.12; 95% CI, 1.07-1.16). Conclusions Patients with PAD and HF have a high rate of coronary artery disease with a high risk for major adverse cardiovascular events and death. These data support the possible need for aggressive treatment of (recurrent) atherosclerotic disease in PAD, especially patients with HF.
- Subjects :
- Age Factors
Aged
Clopidogrel adverse effects
Comorbidity
Female
Heart Failure diagnosis
Heart Failure mortality
Hospitalization
Humans
Male
Middle Aged
Peripheral Arterial Disease complications
Peripheral Arterial Disease diagnosis
Peripheral Arterial Disease mortality
Platelet Aggregation Inhibitors adverse effects
Purinergic P2Y Receptor Antagonists adverse effects
Randomized Controlled Trials as Topic
Risk Assessment
Risk Factors
Ticagrelor adverse effects
Time Factors
Treatment Outcome
Clopidogrel therapeutic use
Heart Failure complications
Peripheral Arterial Disease drug therapy
Platelet Aggregation Inhibitors therapeutic use
Purinergic P2Y Receptor Antagonists therapeutic use
Ticagrelor therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 2047-9980
- Volume :
- 10
- Issue :
- 12
- Database :
- MEDLINE
- Journal :
- Journal of the American Heart Association
- Publication Type :
- Academic Journal
- Accession number :
- 34056910
- Full Text :
- https://doi.org/10.1161/JAHA.120.018684